Quarterly ResultMay 12, 2026, 07:37 AM
Sagimet Q1 Net Loss Narrows to $10.65M; R&D Expenses Down 54%
AI Summary
Sagimet Biosciences reported a significantly reduced net loss of $10.65 million for Q1 2026, down from $18.18 million in Q1 2025, driven by a 54% decrease in research and development expenses. The company's cash, cash equivalents, and marketable securities totaled $104.5 million as of March 31, 2026, and are expected to fund operations for at least the next 12 months, including proceeds from a recent April 2026 underwritten offering. Denifanstat, the lead drug candidate, achieved all primary and secondary endpoints in Phase 3 acne trials in China.
Key Highlights
- Net loss for Q1 2026 narrowed to $10.65 million from $18.18 million in Q1 2025.
- Research and development expenses decreased 54% to $6.99 million from $15.34 million.
- Total operating expenses fell to $11.71 million from $19.87 million year-over-year.
- Net loss per share improved to $(0.33) from $(0.56) in the prior year period.
- Cash, cash equivalents, and marketable securities totaled $104.5 million as of March 31, 2026.
- Net cash used in operating activities improved to $(8.61) million from $(14.54) million.
- Denifanstat met all primary and secondary endpoints in Phase 3 acne trials in China.
- Company expects sufficient funds for at least 12 months, including April 2026 offering.